Monthly Archives: June 2017

Worldwide CNV (Choroidal NeoVascularization) Market Analysis, Trends and Forecast by 2015 – 2023

Choroid is the part of eye that lies in between the retina (vision sensory area) and the sclera (the outer layer of the eye), this area consist of blood vessels that supply nutrients to the retinal part of our eye. Choroidal NeoVascularization (CNV) is a disease, which is characterized by the formation of new blood vessels that arise either due to the presence of Vascular Endothelial Growth Factors (VGEF) or due to Age-related Macular Degeneration (AMD). This results in fluid accumulation below the retinal pigment epithelium, which can lead to vision loss or extreme myopic vision among individuals. CNV is also seen in individuals with diabetic retinopathy. In rare cases, it can occur among individuals with defects in Bruch’s membrane, the innermost layer of the choroid. It has also been observed by the American Academy of Ophthalmology and other reports that patients with CNV in one eye have a very high probability to contract CNV in the other eye within a short frame of time. According to the British Journal of Ophthalmology published in 2007, age?related macular degeneration (AMD) is one of the leading causes of irreversible sight loss among adults registered as legally blind. Among these, two-thirds of people with AMD have the wet form, which can progress quickly causing irreversible sight loss within days or weeks. In 2007, approximately 250,000 people were suffering from neovascular AMD in the U.K, with an incidence rate of 25,000 and 30,000 new cases annually.

Obtain Report Details @
http://www.transparencymarketresearch.com/choroidal-neovascularization-market.html

The only successful treatment option that is available commercially in the market for CNVs include intravitreal (direct to the eye) injections of anti-VEGF drugs to control the neovascularization and reduce the fluid accumulated. The most common anti-VGEF compounds are Ranibizumab (Trade name: Lucentis), Bevacizumab (Trade name: Avastin) and the novel drug Pegaptanib (Trade name: Macugen). These drugs belong to a class called anti-angiogenic drugs, their primary objective being the inhibition of the growth of new blood vessels. Anti angiogenic drugs are more commonly used for cancer treatment, where cancerous cells promote angiogenesis resulting in the proliferation of cells in large numbers, thus forming tumors. Bevacizumab is a successfully used cost effective drug for the treatment of cancer as well as AMD related CNVs with a very high half life (more than twice) in comparison with Ranibizumab. However chances of adverse effects with Bevacizumab are comparatively higher, hence Ranibizumab (Lucentis) is now currently the most effectively and safely used treatment for CNV. Pegaptanib on the other hand is in Phase IV of the clinical trials wherein only 1000 patients so far have been treated with significant success rate.

With increasing aging population throughout the world the probability of occurrence of wet-AMD is high, especially in China and Japan where the aging population is predicted to tip over the young adult population. The patents for both Bevacizumab and Ranibizumab are till 2018 hence after patent expiry it is predicted that their sales shall significantly increase, especially with the entrance of Asian drug manufacturers.

Currently the companies that manufacture Ranibizumab are Novartis (licensed) in global market and Genetech (patented) in the U.S. Bevacizumab too was developed by Roche Pharma in association with Genentech and is currently marketed by Roche internationally. Pegaptanib is manufactured by Eyetch Inc. and marketed by Pfizer Inc.

Pegaptanib has been approved and is available only in North America, Europe, Brazil and Australia. Ranibizumab is available under the name Lucentis with high market share in Europe and North America and growing in Asia-Pacific region. Bevacizumab is sold as Avastin globally with highest growth rate observed in Asia and highest voluminous growth seen in the North Americas and European markets.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8194

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Hypercholesterolemia Market – Worldwide Industry Analysis and Forecast 2015 – 2023

Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol reduces the risk for heart diseases and HDL naturally removes cholesterol from cells by reverse cholesterol transport to the liver. On the other, hand LDL adds to plaque, a hard and dense deposit that blocks the arteries and make the artery wallless flexible. This type of medical condition is termed as atherosclerosis. Clot forms and blocks the narrowed arteries leads to heart attack, stroke and peripheral artery diseases.

Obtain Report Details @
http://www.transparencymarketresearch.com/hypercholesterolemia-market.html

Hypercholesterolemia usually result from the grouping of genetic and environmental risk factors. Genetic disorder leads to heterozygous familial hypercholesterolemia. It happens due to the existence of the mutated copy of the LDLR gene (LDL receptor gene). Individuals with the homozygous gene, containing dual copies of the gene mostly suffer from severe cardiovascular diseases in their childhood and people with the heterozygous gene that is with a solitary copy of the gene suffer from cardiac ailment in their 30s or 40s.

Hypercholesterolemia due to lifestyle selections includes unhealthy eating habits, lack of exercise, and intake of tobacco smoking strongly hampers the quantity of cholesterol in the blood. However, there are few secondary reasons as well such as diabetes mellitus (Type 2), alcohol intake, obesity, monoclonal gammopathy, dialysis and others.

The hypercholesterolemia treatment market is increasing at a substantial rate due to technologically advanced diagnosis, government initiatives, improved reimbursement scenario lifestyle changes, rising awareness about different cardiovascular diseases. Treatment for hypercholesterolemia mainly includes intake of statins and opting for a better lifestyle. Factors such as high cost in the diagnosis, lack of awareness and lack of knowledgeable experts for proper diagnosis of the disease are restricting the global market for hypercholesterolemia treatment.

North America rules the global market for hypercholesterolemia treatment reason beingincreased incidences of heart diseases and related disorders in the region. Asia, followed by Europe, predicted to witness a high growth rate in coming years in the hypercholesterolemia market. Developing countries like China and India are also growing fast in these markets by the presence of a large patient pool and growing government initiatives. Hypercholesterolemia Market can be segmented as drug class and geography. Drug class can categorize hypercholesterolemia market as statins, niacin, bile-acid resins, fibric acid derivatives, cholesterol absorption inhibitors.

Some of the key players in this Hypercholesterolemia market AbbVie, Inc., AstraZeneca Plc., Amgen, Inc., Eli Lilly and Company, Merck & Co., Novartis AG and Pfizer, Tekmira Pharmaceuticals Corporation.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8176

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Worldwide Bacterial Disease Diagnostic Market Share by Industry Research 2015 – 2023

Bacteria are of various types some of them are infectious whereas, majority of them are beneficial for the body. Any bacteria that cause an infectious disease are called pathogens. Diagnosis of causative organism of a bacterial disease has always been difficult, since infections show similar symptoms like fever and lethargy. Routine clinical diagnosis have high error rate, administering the wrong antibiotics can sometimes increase infection and can even result in death. The oldest method for diagnosis has been culturing of bacteria, these cultures allow only specific species to grow in the medium, however this method is very time consuming and can seldom be done on time to successfully diagnose and treat the patient. Newer techniques like rapid culture methods with ionized mass spectrometry are currently in use for diagnosing some rare bacteria.

Obtain Report Details @
http://www.transparencymarketresearch.com/bacterial-disease-diagnostic-market.html

Currently, PCR (Polymerase Chain Reaction) sequencer is the most favored and well know method. The PCR can amplify bacterial DNA a thousand times if necessary, any routine diagnosis requires only a min of 10 – 80 bacteria, which means PCR has a very high sensitivity. This factor is exploited for countless diagnostic processes. PCR also doesn’t require purification of the bacterial sample compared to older methods as it has specific sequences to identify bacterial DNA. Versatility of PCR has proven to be a big advantage, diagnosis of many dangerous diseases like tuberculosis, pneumonia etc are done with the intention to specify whether the strain is drug resistant. This greatly increases the success rate of treatment. The shortcomings of PCR are also eminent; PCR is susceptible to false positive report in presence of any contamination, it is also not useful in calculating the success of a treatment, as PCR recognizes dead and living cells as the same. Technical expertise is a major requirement in PCR handling. PCR techniques also require a number of biochemical reagents that are quite expensive. Development has been made to create more specific and customized versions of PCR machines with greater accuracy and low false positive rates. These include; PCR ribotyping techniques which are much faster and highly specific to certain strains; multiplex PCR that can detect multiple pathogens in a single go and nested PCR a modified error negating version of PCR. Such modified versions are currently available in laboratories and are offered as a diagnostic service and are seldom used as a large-scale diagnostic tool. However, with the entry of novel ‘portable PCR’ there is a scope for diagnostic evolution in future.

On the other hand, scientists throughout the world are developing ideas in Electrophoresis methods and tests for biological proteins that are produced in the body in reaction to an infection. In newborns such tests are done to investigate the diseases that have late onset period. With increasing population and globalization, the chance of infection remains high, diseases too have gone global. In addition, diagnosing a disease before it becomes an epidemic is very critical. Thus, PCR and electrophoresis machines helps in early and fast diagnosis of these diseases that leads to an increase in the demand for PCR and electrophoresis machines. However, lack of skilled professionals/technicians and high cost of these devices restricts the overall growth of bacterial disease diagnostics market.

Some of the companies that produce PCR machines are Techne, GeneriBiotech, Roche diagnostics and ZyGEM to name a few. The sales of these devices are currently highest in the developed nations of the North Americas and Europe whereas, Asia-Pacific region shows the highest growth followed by South America and Africa.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7823

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Competitive Landscape for Worldwide Vascular Endothelial Growth Factor Antibodies Market by Segments – 2024

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Overview

Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals. Currently, VEGF antibodies used for treating cancer contribute more than half the total revenue of the global market. Some of the popular antibodies other than Avastin in the global market are Eylea (aflibercept, Bayer Pharma AG), Cometriq (cabozantinib, Exelixis, Inc.), Jetrea, Cyramza (ramucirumab, Eli Lilly and Company), Macugen (pegaptanib, Valeant Pharmaceuticals), Zaltrap (ziv-aflibercept, Regeneron Pharmaceuticals, Inc.), and Lucentis (ranibizumab, Genentech).

Obtain Report Details @
http://www.transparencymarketresearch.com/vascular-endothelial-growth-factor-antibodies-market.html

The research report by Transparency Market Research provides a thorough outlook of the global VEGF antibodies market. The research report includes SWOT analysis and Porter’s five forces analysis for an in-depth understanding of the ever-changing market dynamics. The publication includes recommendations and comments by expert market leaders in order to help the readers gain holistic knowledge. The unbiased review of the market is aimed at providing guidance to the readers for making well-informed business decisions. For an accurate and an exact assessment of the information, the research report has been compiled using primary and secondary research methodologies.

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Key Trends

The global VEGF antibodies market is expected to see entry of several biosimilars manufacturing companies as first generation VEGR antibodies are reach their patent expiry. This trend has also opened up several opportunities for companies that have been developing next generation products. The launch of promising therapies in the foreseeable future will offer users tremendous convenience.

The increasing investments in research and development are also expected to play an instrumental role in shaping the trajectory of the global market. For instance, increasing focus on developing personalize medicines and diagnostics will lead to generation of targeted therapies, thereby helping patients to receive optimized therapy. Efficient therapies and reduction of toxicities will ensure high uptake of these products in the near future.

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Regional Outlook

From a geographic point of view, the global VEGF antibodies market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Of these, North America and Europe are projected to lead the global market in the coming years due a well-structured healthcare sector in the developed regions. Furthermore, growing diagnostic centers that have brought forth the increasing prevalence of cancer in the region have also augmented the demand for VEGF antibodies.

Analysts expect that developing regions of Africa and Asia Pacific are also expected to be lucrative markets for VEGF antibodies in the near future. Countries such as India and China are expected to dominate the Asia Pacific market as big players are looking at developing nations for expansion and collaborations.

Key Players Mentioned in the Report are:

Some of the leading players operating in the global VEGF antibodies market are Genentech (a Roche company), Exelixis, Inc., Abcam plc, Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd (a subsidiary of Circardian Technologies Limited), BioVision, Inc., and Santen Pharmaceutical Co. Ltd. The research report explains the competitive landscape present in the global VEGF antibodies market in the complete detail.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7286

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Worldwide Gastrointestinal Electrocardiograph Market By Geography Products Analyzers 2015 – 2023

The global market for gastrointestinal electrocardiograph is anticipated to witness a steady growth during the forecast period from 2014 to 2020. This growth is likely to support by the factors such as high prevalence of gastric disorders, increased use of advanced diagnostic technologies and growing medical infrastructure and healthcare expenditure. Large prevalence of chronic gastrointestinal diseases is another important propeller of the market growth. According to a report of National Digestive Diseases Information Clearinghouse (NDDIC), in the U.S., around 70 million people were affected by various types of digestive diseases in 2010. The report further states that around 245,000 people were killed in 2009, due to gastrointestinal diseases. Thus, high prevalence of chronic gastric diseases accelerates the market growth. Furthermore, according to the statistics provided by the Office for National Statistics, Government of the U.K., the healthcare expenditure of the U.K. has expanded from USD 101.8 billion in 2000 to USD 233.4 billion in 2012. This exponential growth in the healthcare expenditure of the developed countries (the U.S., the U.K. and Japan) propells strong development of medical infrastructure, which ultimately supports the growth of gastrointestinal electrocardiograph market. On the other hand, high cost and lack of awareness are the key restraints that may limit the market growth to some extent.

Obtain Report Details @
http://www.transparencymarketresearch.com/gastrointestinal-electrocardiograph-market.html

Gastrointestinal diseases are mild to chronic disorders related to gastrointestinal tract (GIT), which includes diseases related to esophagus, stomach, intestines, liver, pancreas and other associated body organs. Gastrointestinal diseases may or may not be life-threatening. Gastrointestinal disorders are usually chronic in nature and cause severe inflammation and irritation of bowel.

A large number of diagnostic tests and tools are used in the diagnosis of gastrointestinal diseases. These techniques mainly include endoscopy, electrogastrograph (EGG), MRI scanning and CT scans. Gastrointestinal electrocardiograph, also known as electrogastrograph (EGG) is a technique to measure action potentials of the stomach. The main aim of measuring action potential of stomach is to evaluate gastric motility and to determine the relation between EGG and identify the diseases related to stomach and GIT. The physiological basis of EGG underlies the motility of GI tract. The motility of GI tract is based on contractions of smooth muscle, which in turn is based on two patterns of electrical activity, namely; action potential and slow waves. Slow waves in GIT are initiated by the interstitial cells of Cajal (ICC). The maximum frequency of muscle contraction ranges from 3 waves in a minute (stomach) to 17 waves per minute (rectum).

The market of gastrointestinal electrocardiograph is segmented on the basis of types of EGG, such as electrogastroenterography (EGEG) and cutaneous electrogastrography. Further, the market is also segmented on the basis of applications (gastric diseases diagnosis), such as gastric cancer diagnosis, irritable bowel syndrome, functional dyspepsia, peptic ulcer, motility disorders (vomiting, nausea, delayed gastric emptying) and others. Moreover, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). Currently, the North American region is the most lucrative market, owing to large number of patients diagnosed with gastrointestinal diseases and increased demand for advanced diagnostic technologies. However, Asia-Pacific is considered as the most promising market during the forecast period from 2014 to 2020, owing to rising prevalence of disease and increasing awareness about the GIT diseases, its symptoms, diagnostic tests and treatment.

Some of the major players operating in this market include Synectics Medical, 3CPM Company, and Gastroscan amongst others.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6865

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Worldwide Outlook for Companion Animal Vaccines Market By Key Trends and Analysis 2024

The companion animal vaccines market has seen an uptick in revenues in keeping with the growing popularity of keeping pets at home. Regular planned vaccinations are now regarded as being integral to the entire pet rearing and maintenance process. Consequently, the formulation of newer varieties of companion animal vaccines is helping this progress. Companion animal vaccines are administered not just to pets such as dogs, cats, pet reptiles, and the like, but also to livestock.

TMR projects a positive outlook for the global companion animal vaccines market in the near future. The market is expected to grow on account of the burgeoning number of pet owners in developing regions as well. The report is a comprehensive compilation of the emergent trends that are projected to palpably impact the future of this market and how companies are responding to this change.

Obtain Report Details @
http://www.transparencymarketresearch.com/companion-animal-vaccines-market.html

As sweeping societal changes occur worldwide, the trend of having animals as companions is on the rise. Many lonely aged people, nuclear families, and single persons are choosing to have an animal in their household. Estimates show that in the United States alone, about 62% of all households have a pet. Pet ownership numbers are also rising in other countries worldwide.

However, animals are also the carriers of various diseases and infections that could be contracted by humans around them. Likewise, companion animals also stand the risk of contracting infections or diseases from humans around them. Vaccination is thus an important aspect that pet owners are urged not to neglect – for the safety of both the pets and owners alike.

Global Companion Animal Vaccines Market: Key Drivers and Restraints

Concerns associated with the rising prevalence of zoonotic diseases and the discovery of new diseases among animals are providing a push to the companion animal vaccines market. Besides this high-impact driver, the market is also gaining from the growing focus on implementing animal welfare initiatives and governments laying more emphasis on keeping animal-related diseases in check.

However, developing animal vaccines is a rather lengthy and expensive process – the impact of which can be seen in the form of the high prices that these vaccines command. That puts them beyond the reach of some consumer classes, especially if suitable reimbursement schemes are not available to them. The other factor that is negatively impacting the companion animal vaccines market for livestock is the growing number of vegetarians in the world who may consume dairy products but not meat.

Global Companion Animal Vaccines Market: Key Segments

The report classifies the global companion animal vaccines market basis the following criteria: diseases, product, and technology. Based on product type, the market is segmented into feline, canine, bovine, and others. Likewise, the diseases for which companion animal vaccines are available include: Rabies, hepatitis, leukemia, and others.

By technology used for the development and formulation of the vaccine, the global companion animal vaccines market has been segmented thus: DNA, recombinant, inactivated, toxoid, conjugate, and other vaccines. Considerable research is being undertaken to formulate more effective vaccines with lower price tags.

Global Companion Animal Vaccines Market: Regional Outlook

The global market for companion animal vaccines has been segmented as follows: Asia Pacific, North America, Europe, and Rest of the World. TMR projects the market to fare well in North America and Europe, where pet ownership numbers as well as meat consumption have been traditionally high. Europe currently accounts for a sizeable share in the global companion animal vaccines market.

In Latin American and Asian countries, a new class of affluent consumers is emerging. These consumers are keener on having a companion animal in their household and will thus fuel the global market for companion animal vaccines. The vast population here and the untapped opportunities mean that market players have considerable gains to make by targeting these regions.

Top players in the global companion animals market are: Merial Inc. (Sanofi), Bayer Healthcare, Boehringer Ingelheim (Germany), Novartis Animal Health Inc., and Merck Animal Health (U.S).

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11390

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Worldwide Artificial Pancreas Device System Market Trends & Industry Forecast by 2016 – 2024

Global Artificial Pancreas Device System Market: Overview

According to World Health Organization (WHO) estimates, 422 million people were diagnosed with diabetes across the globe in 2014. Diabetes is considered one of the leading causes of death in a majority of developed nations, while it is emerging as a larger issue in developing nations. Effective therapeutic measures are required to keep the blood glucose levels of diabetic patients close to normal. Constant monitoring of blood glucose levels is thus important to lower the risk of hypoglycemic episodes in diabetic patients. This is a key factor fueling the demand for artificial pancreas device systems (APDS).  APDS is an innovative device used for monitoring blood glucose level and administering insulin in appropriate doses to people suffering from diabetes.

Obtain Report Details @
http://www.transparencymarketresearch.com/artificial-pancreas-device-system-market.html

Increase in the incidence of diabetes has made patient-specific care extremely important. An artificial pancreas device system helps in effectively treating diabetes patients. It is designed as a closed yet continuous loop control system required for insulin infusion. The continuous control is intended to facilitate the daily treatment of diabetic patients, especially in cases where medical personnel are not available round the clock or patients have little knowledge about the ailment.

An APDS, therefore, mimics the glucose regulating functions performed by a healthy pancreas. The system is also used to administer insulin to type 2 diabetes patients. Apart from the constant monitoring of blood glucose levels, the system provides optimum balance between blood glucose and insulin in patients. This prevents the occurrence of other diabetes-related disorders such as cardiac arrest and kidney failure.

The report provides a qualitative and quantitative assessment of the various factors affecting the global APDS market’s growth trajectory. It presents insights into the prevailing market trends and compiles exhaustive information relating to the most lucrative regional markets for APDS. Using industry-leading analytical tools, the report presents the information thus obtained in a logical format.

Global Artificial Pancreas Device System Market: Key Opportunities and Threats

Increase in demand for organ transplant and growing prevalence of pancreatic disorders are expected to drive the global artificial pancreas device system market. Rising incidence of pancreatic cancer and pancreatitis and increasing number of diabetics across the world are also fueling demand for advanced technologies.

The market is gaining impetus from increasing consumption of alcohol and other factors that increase the risk of developing pancreatic disorders. Additionally, prevalence of ailments and medical conditions such as lupus and high triglycerides and gallstones is propelling the market. Furthermore, rising geriatric population with pancreatic disorders and introduction of latest technologies such as software based and wireless systems are expected to boost market growth. However, growing awareness about the side effects of the treatment modality and ineffectiveness of this technology in treating athletic diabetes are likely to hamper market growth.

Global Artificial Pancreas Device System Market: Regional Outlook

Regionally, the global artificial pancreas device system market has been segmented into North America, Asia Pacific, Europe, and Rest of the World. India, Indonesia, China, Pakistan, Japan, and the U.S. are the top countries exhibiting the highest incidence of diabetes. Hence, Asia Pacific and North America have emerged as the most lucrative markets for artificial pancreas device systems.

In order to study the prevailing competitiveness in the market, the report profiles companies based on their financial overview, strategies adopted, and product portfolio. Some of the leading players in the APDS market are Johnson & Johnson, Pancreum LLC, and JDRF.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11234

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/